Buy PRCT on the Dip: A Patient Long on Robotic Urology Growth
PROCEPT BioRobotics (PRCT) is a commercial-stage surgical robotics company focused on Aquablation for BPH. The stock trades at $26.49 with a $1.49B market cap after a February guidance cut and a subsequent wave of negative headlines. Fundamentals show rapid prior top-line growth, a strong liquidity position, and an EV/sales ratio that can compress …